Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: Implications for clinical practice

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 2, 2012, Pages 99-110

  Grillo, Joseph A ^a   Zhao, Ping ^a   Bullock, Julie ^a   Booth, Brian P ^a   Lu, Min ^a   Robie Suh, Kathy ^a   Berglund, Eva Gil ^b   Pang, K Sandy ^c   Rahman, Atiqur ^a   Zhang, Lei ^a   Lesko, Lawrence J ^a   Huang, Shiew Mei ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Complex drug interactions; Physiologically based pharmacokinetic modeling (PBPK); Renal impairment

Indexed keywords

ERYTHROMYCIN; RIVAROXABAN;

ADULT; AGED; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG METABOLISM; HUMAN; KIDNEY DYSFUNCTION; PHARMACOKINETICS; PHYSIOLOGICALLY BASED PHARMACOKINETIC; PREDICTION; REVIEW;

ADULT; AGED; DRUG INTERACTIONS; EVALUATION STUDIES AS TOPIC; FORECASTING; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; MORPHOLINES; PHYSIOLOGICAL PHENOMENA; THIOPHENES; YOUNG ADULT;

EID: 84862776909     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1771     Document Type: Review

References (41)

1. Janssen Pharmaceuticals, Inc. XARELTO® (rivaroxaban) package insert. Titusville, NJ; 2011. http://www.xareltohcp.com/xarelto-prescribing-information. html 1-27-2012.
2. US FDA. Approval History, NDA 022406 Xarelto (rivaroxaban) 10mg immediate release Tablets. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2011/ 022406s000ltr.pdfhttp://www.accessdata.fda.gov/drugsatfda-docs/appletter/2011/ 022406s000ltr.pdf.
3. European Medicines Agency. Summary of Product Characteristics or SPC: Xarelto. Accessed September 6, 2011. www.ema.europa.eu/docs/en-GB/document- library/EPAR---Product-Information/human/000944/WC500057108.
4. European Medicines Agency. CHMP Assessment Report: Xarelto. Accessed September 6, 2011. www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public- assessment-report/human/000944/WC500057122.
5. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880. (Pubitemid 41803696)
6. Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008; 24: 2757-2765.
7. Lang D, Freudenberger C, Weinz C. In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. Drug Metab Dispos 2009; 37: 1046-1055.
8. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 37: 1056-1064.
9. US FDA. FDA Advisory Committee Briefing Document: Cardiovascular and Renal Drugs Advisory Committee. March 19, 2009: 220-34. www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM181524. pdf 9-6-2011.
10. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 2011; 338: 372-380.
11. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421. (Pubitemid 41393676)
12. Nestorov IA, Aarons LJ, Arundel PA, Rowland M. Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokinet Biopharm 1998; 26: 21-46. (Pubitemid 28429460)
13. Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 2000; 17: 419-426. (Pubitemid 30395296)
14. Rowland YK, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazemon the time-course of exposure to triazolam. Eur J Pharm Sci 2010; 39: 298-309.
15. Yang J, Kjellsson M, Rostami-Hodjegan A, Tucker GT. The effects of dose staggering on metabolic drug-drug interactions. Eur J Pharm Sci 2003; 20: 223-232. (Pubitemid 37205216)
16. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. The Simcyp((R)) Population-based ADME Simulator. Expert Opin Drug Metab Toxicol 2009; 5: 211-223.
17. Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007; 6: 140-148. (Pubitemid 46745341)
18. Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a 'well-stirred'model and a 'parallel tube' model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977; 5: 625-653. (Pubitemid 8253670)
19. Eberl S, Renner B, Neubert A, et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 2007; 46: 1039-1049. (Pubitemid 350136910)
20. Kurihara A, Hagihara K, Kazui M, Ozeki T, Farid NA, Ikeda T. In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation. Drug Metab Rev 2005; 37(Suppl 2): 99.
21. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010; 70: 703-712.
22. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006; 46: 549-558.
23. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007; 63: 469-476. (Pubitemid 46426627)
24. Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 2009; 24: 53-75.
25. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
26. Zhao P, Zhang L, Huang SM. Complex drug interactions: significance and evaluation. In Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges. Pang KS, Rodrigus AD, Peter RM (eds). Springer: New York, 2010; 667-692.
27. Aarons L. Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. Br J Clin Pharmacol 2005; 60: 581-583. (Pubitemid 41705376)
28. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45-73.
29. Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 2011; 89: 259-267.
30. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008; 4: 1065-1074.
31. Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 2008; 83: 898-903. (Pubitemid 351704931)
32. Nolin TD. Altered nonrenal drug clearance in ESRD. Curr Opin Nephrol Hypertens 2008; 17: 555-559.
33. Yeo KR, Aarabi M, Jamei M, Rostami-Hodjegan A. Modelling and predicting drug pharmacokinetics in patients with renal impairment. Expert Opin Clin Pharmacol 2011; 4: 261-274.
34. Zhao P, Vieira M de LT, Grillo JA, et al. Evaluation of exposure change of non-renally eliminated drugs in patients with chronic kidney disease using physiologically-based pharmacokinetic modeling and simulation. J Clin Pharmacol 2012; 52: 91S-108S.
35. Jones JP, Katayama JH, Jiang Y, Lee CA, Totah RA. Identification of danazol as a selective inhibitor of cytochrome P450 2 J2. 15th North American regional meeting of International Society for the Study of Xenobiotics, October, 2008, San Diego, CA, USA.
36. Wang YH. Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors. Drug Metab Dispos 2010; 38: 1094-1104.
37. Xu L, Chen Y, Pan Y, Skiles GL, Shou M. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator. Drug Metab Dispos 2009; 37: 2330-2339.
38. Dette GA, Knothe H, Herrmann G. Erythromycin binding to human serum. Biochem Pharmacol 1982; 31: 1081-1087. (Pubitemid 12147952)
39. Austin KL, Mather LE, Philpot CR, McDonald PJ. Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 1980; 10: 273-279. (Pubitemid 10049166)
40. Barre J, Mallat A, Rosenbaum J, et al. Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol 1987; 23: 753-757. (Pubitemid 17087978)
41. Josefsson K, Bergan T, Magni L. Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base. Br J Clin Pharmacol 1982; 13: 685-691. (Pubitemid 13139885)